Intel stock extends gains after report of possible U.S. government stake
BOSTON - Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a biotechnology firm with a market capitalization of $10.7 million, reported preliminary results from a clinical trial evaluating solnerstotug, a new cancer therapy. The Phase 1/2 trial demonstrated an overall response rate (ORR) of 14% in patients resistant to PD-(L)1 inhibitors, a standard treatment for various cancers. This rate is nearly three times the expected response for patients rechallenged with PD-(L)1 therapies, addressing a significant unmet medical need. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt, though it’s currently unprofitable with an EBITDA of -$31.26 million in the last twelve months.
The study included 60 patients with "hot" tumors, such as Non-Small Cell Lung Cancer and Merkel Cell Carcinoma, which had progressed following previous immunotherapy treatments. A notable outcome was a durable complete response in a Merkel Cell Carcinoma patient who has been on treatment for over 42 weeks. Additionally, two partial responses were observed in another Merkel Cell Carcinoma patient and a microsatellite instability-high Colorectal Cancer patient, both of whom had previously progressed on immunotherapy.
Sensei’s Chief Medical Officer, Dr. Ron Weitzman, expressed optimism about the early data, suggesting solnerstotug may provide a meaningful clinical benefit in select tumor types. The therapy was well tolerated, with the majority of adverse events being mild and manageable.
Despite these positive findings, no responses were observed in patients with microsatellite stable Colorectal Cancer, a "cold" tumor type that is typically unresponsive to immunotherapy.
Sensei plans to initiate a Phase 2 study in Q1 2026, informed by ongoing dose expansion results. The design will include biomarker-based patient selection to optimize outcomes. The company will host an investor webcast featuring company leadership and Dr. Shiraj Sen, a principal investigator for the study, to discuss the findings. InvestingPro analysis shows the company’s current Fair Value suggests it may be undervalued, with analyst price targets ranging from $3.50 to $4.00 per share. Subscribers can access 8 additional ProTips and comprehensive financial metrics to better understand Sensei’s investment potential.
This news is based on a press release statement from Sensei Biotherapeutics. The company continues to investigate the potential of solnerstotug, aiming to address the challenge of secondary resistance in cancer treatment, which affects patients who have progressed following initial treatments with PD-(L)1 immune checkpoint inhibitors. The company’s financial health score of 2.3 (FAIR) on InvestingPro reflects its current development stage status, with a cash burn rate that warrants monitoring as it advances its clinical programs.
In other recent news, Sensei Biotherapeutics, Inc. is facing potential delisting from the Nasdaq Stock Market due to its stock price not meeting the required minimum bid price. The company disclosed receiving a second notice from Nasdaq, which highlighted that while its application to transfer to the Nasdaq Capital Market has been approved, it must regain compliance with the minimum bid price by July 7, 2025. Initially notified on July 12, 2024, for not meeting the $1.00 minimum bid price over the previous 30 consecutive business days, Sensei Biotherapeutics was given an initial 180-day period, ending on January 6, 2025, to resolve the issue. However, the company has yet to meet this requirement. Consequently, Sensei Biotherapeutics will be transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market on January 8, 2025, and will continue trading under the ticker symbol "SNSE." The company plans to actively monitor its stock’s closing bid price and consider all available options, including a reverse stock split, to regain compliance. If the required bid price is not achieved by the second compliance date, Nasdaq will issue a notice of delisting, though the company could appeal this decision. The effectiveness of Sensei Biotherapeutics’ efforts to maintain its listing status remains uncertain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.